News World AstraZeneca resumes trials of COVID vaccine halted by patient illness

AstraZeneca resumes trials of COVID vaccine halted by patient illness

AstraZeneca has resumed British clinical trials of its COVID-19 vaccine, one of the most advanced in development, after receiving the green light from safety watchdogs, the company said on Saturday.

The late-stage trials of the experimental vaccine, developed with researchers from the University of Oxford, were suspended this week after an illness in a study subject in Britain, casting doubts on an early rollout.

“On 6 September, the standard review process triggered a voluntary pause to vaccination across all global trials to allow review of safety data by independent committees, and international regulators,” AstraZeneca said.

It added that safety reviewers had recommended to Britain’s Medicines Health Regulatory Authority (MHRA) that it was safe to resume the UK trials.

The patient involved in the study had been reportedly suffering from neurological symptoms associated with a rare spinal inflammatory disorder called transverse myelitis.

AstraZeneca, based in Cambridge, said it could not disclose further medical information.

Governments around the world are desperate for a vaccine to help end the pandemic, which has caused more than 900,000 deaths and global economic turmoil. The World Health Organisation (WHO) had flagged AstraZeneca’s as the most promising.

The pause of the trials came after reports that the United States was aiming for fast-track authorisation or approval of a vaccine before November’s presidential election.

Leading U.S. and European vaccine developers have pledged to uphold scientific safety and efficacy standards for their experimental vaccines and not bow to political pressures to rush the process.

AstraZeneca has already agreed to supply close to three billion doses to governments across the globe – more than any other vaccine project.

The WHO’s chief scientist said the pause in the trial should serve as a “wake-up” call that there would be ups and downs in the development of a vaccine.

(Reuters)

Top Stories

310 new cases through PCR tests announced on Friday

The Health Ministry announced 310 new Coronavirus cases out of 6,584 PCR tests on Friday 27 November and another out of 6, 311 rapid...

Health Minister concerned about situation in old people’s homes

Health Minister Konstantinos Ioannou expressed his concern about the COVID-19 cases found in old people’s homes. However, he noted that within the framework of...

NPLs in the Cyprus banking system down by €132 million in July

Non- Performing Loans (NPLs) in the Cyprus banking system dropped by €132 million continuing their downward trajectory, assisted by disposals as well as the...

Health Ministry prepares plan for COVID-19 vaccination

The plan, which will be followed by the Ministry of Health, for vaccination against the coronavirus has already been prepared, said today to CNA...

Cyprus second in EU regarding first residence permits

In 2019, about 3.0 million first residence permits were issued in the EU to non-EU citizens. The number rose by 6% (or 163 000)...

Taste

Squash soup

Ingredients: 1 kg pumpkin, cut into small cubes, approximately 5 cups 2 medium (400g) sweet potatoes, cut into cubes, approximately 2 ½ cups 1 chopped leek, only...

Mezedes

No visit to Cyprus is complete without enjoying the traditional meal of many small dishes known as ‘meze’. This large feast, which has been a...

Prawns with fried cheese, barley shaped pasta

Put the barley shaped pasta into a small pan with salted water, bring to a boil and when tender, drain. Peal the prawns leaving...

Salmon and shrimp sheftalies

Mix all ingredients for tabbouli in a bowl and keep to one side so flavours can combine. Prepare the sheftalies: wash and soak the casing...